Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) Receives $40.00 Consensus Price Target from Analysts

Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) has received a consensus recommendation of “Hold” from the five research firms that are covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating on the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $46.25.

A number of equities research analysts recently issued reports on SNSE shares. Citigroup started coverage on Sensei Biotherapeutics in a research report on Friday, May 22nd. They issued a “buy” rating and a $55.00 target price on the stock. Zacks Research raised Sensei Biotherapeutics to a “hold” rating in a research report on Tuesday, April 21st. Leerink Partners started coverage on Sensei Biotherapeutics in a research report on Monday, April 20th. They issued an “outperform” rating and a $50.00 target price on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Sensei Biotherapeutics in a research report on Friday, April 24th. Finally, Loop Capital set a $50.00 target price on Sensei Biotherapeutics in a research report on Thursday.

Sensei Biotherapeutics Trading Up 5.6%

SNSE stock opened at $17.59 on Friday. The stock has a 50-day moving average price of $26.60 and a two-hundred day moving average price of $18.46. The stock has a market cap of $23.57 million, a PE ratio of -0.12 and a beta of -0.18. Sensei Biotherapeutics has a 1 year low of $5.31 and a 1 year high of $36.76.

Sensei Biotherapeutics (NASDAQ:SNSE) last announced its earnings results on Friday, May 15th. The company reported ($131.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.62) by ($130.83). On average, analysts forecast that Sensei Biotherapeutics will post -2.77 earnings per share for the current fiscal year.

Insider Transactions at Sensei Biotherapeutics

In related news, major shareholder Millennium Management Llc sold 8,151 shares of Sensei Biotherapeutics stock in a transaction that occurred on Tuesday, April 7th. The stock was sold at an average price of $31.01, for a total value of $252,762.51. Following the sale, the insider owned 133,986 shares of the company’s stock, valued at approximately $4,154,905.86. This trade represents a 5.73% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Over the last quarter, insiders purchased 46,980 shares of company stock valued at $1,341,669 and sold 23,067 shares valued at $704,439. Corporate insiders own 23.20% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. Vivo Capital LLC bought a new position in Sensei Biotherapeutics in the first quarter valued at approximately $22,758,000. Stempoint Capital LP bought a new position in Sensei Biotherapeutics in the first quarter valued at approximately $4,188,000. Bank of America Corp DE grew its stake in Sensei Biotherapeutics by 10,692.5% in the first quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock valued at $1,041,000 after purchasing an additional 32,719 shares in the last quarter. Finally, Renaissance Technologies LLC grew its stake in Sensei Biotherapeutics by 178.2% in the first quarter. Renaissance Technologies LLC now owns 32,041 shares of the company’s stock valued at $1,010,000 after purchasing an additional 20,525 shares in the last quarter. 10.50% of the stock is currently owned by institutional investors.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.